{"id":2089,"date":"2016-12-01T06:41:48","date_gmt":"2016-12-01T06:41:48","guid":{"rendered":"http:\/\/europeanvenousforum.org\/?page_id=2089"},"modified":"2018-02-16T05:34:08","modified_gmt":"2018-02-16T05:34:08","slug":"17th-evf-london-industry-sponsored-symposia","status":"publish","type":"page","link":"https:\/\/europeanvenousforum.org\/index.php\/17th-evf-london-industry-sponsored-symposia\/","title":{"rendered":"17th EVF London Industry Sponsored Symposia"},"content":{"rendered":"

Industry Sponsored Symposia<\/strong><\/span><\/h2>\n

<\/h3>\n

 <\/p>\n

Thursday 7 July 2016<\/span><\/strong><\/span><\/h3>\n\n\n\n
11:00-12:00<\/span><\/td>\nDidactic Session 1:\u00a0Sulodexide <\/strong><\/span>(Supported by an educational grant from Alfa Wassermann)<\/em><\/p>\n

Chairmen: Andrew Nicolaides (Cyprus), Guiseppe Maria Andreozzi (Italy)
\n<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
11:00<\/span><\/td>\nBiomarkers in chronic venous disease and deep venous disease. Ferdinando Mannello (Italy)<\/em><\/span><\/td>\n<\/tr>\n
11:15<\/span><\/td>\nSulodexide in chronic venous disease and deep venous disease recurrence. Tomasz Urbanek (Poland)<\/em><\/span><\/td>\n<\/tr>\n
11:30<\/span><\/td>\nPharmacological rationale behind the clinical effects of Sulodexide. Jawed Fareed (USA)<\/em><\/span><\/td>\n<\/tr>\n
11:45<\/span><\/td>\nDiscussion. Moderator: Andrew Nicolaides (Cyprus)
\n<\/em><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

 <\/p>\n

Thursday 7 July 2016<\/strong><\/span><\/h3>\n\n\n\n
16:30-17:30<\/span><\/td>\nDidactic Session 4:\u00a0Lymphoedema <\/strong><\/span>(Supported by an educational grant from Sigvaris)<\/em><\/p>\n

Chairmen: Christine Moffat (UK), Sophie Renton (UK)<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
16:30-16:45<\/span><\/td>\nThe new classification of primary lymphatic dysplasias and prognosis.\u00a0Sohar Mansour (UK)<\/em><\/span><\/td>\n<\/tr>\n
16:45-17:00<\/span><\/td>\nThe Management of lymphedema including the patient journey. Tracy Green (UK)<\/em><\/span><\/td>\n<\/tr>\n
17:00-17:15<\/span><\/td>\nThe use of compression therapy and IPC in the management of lymphedema. Christine Moffat (UK)<\/em><\/span><\/td>\n<\/tr>\n
17:15-17:30<\/span><\/td>\nDiscussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

 <\/p>\n

Friday 8 July 2016<\/strong><\/span><\/h3>\n\n\n\n
11:00-12:00<\/span><\/td>\nDidactic Session 5:\u00a0The place of ruscus extract + HMC + VitC in the management of chronic venous disease <\/strong><\/span>(Supported by an educational grant from Pierre Fabre)<\/em><\/p>\n

Chairmen: Andrew Nicolaides (Cyprus), Pavel Poredos (Slonenia)
\n<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
11:00-11:15<\/span><\/td>\nMuscarinic receptors in chronic venous disease and the effect of Ruscus. Eliete Bouskela (Brazil)<\/em><\/span><\/td>\n<\/tr>\n
11:15-11:30<\/span><\/td>\nChronic venous disease pathophysiology update. Arkadiusz Jawien (Poland)<\/em><\/span><\/td>\n<\/tr>\n
11:30-11:45<\/span><\/td>\nUpdate on Ruscus extract + HMC + VitC comprehensive mode of action and efficacy. Francois-Andr\u00e9 Allaert (France)<\/em><\/span><\/td>\n<\/tr>\n
11:45-12:00<\/span><\/td>\nPanel Discussion and Conclusions.<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Industry Sponsored Symposia   Thursday 7 July 2016 11:00-12:00 Didactic Session 1:\u00a0Sulodexide (Supported by an educational grant from Alfa Wassermann) Chairmen: Andrew Nicolaides (Cyprus), Guiseppe Maria Andreozzi (Italy) 11:00 Biomarkers in chronic venous disease and deep venous disease. Ferdinando Mannello (Italy) 11:15 Sulodexide in chronic venous disease and deep venous \u2026 Continue reading → <\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-onecolumn.php","meta":{"_exactmetrics_skip_tracking":false,"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-2089","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/2089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/comments?post=2089"}],"version-history":[{"count":3,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/2089\/revisions"}],"predecessor-version":[{"id":2103,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/2089\/revisions\/2103"}],"wp:attachment":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/media?parent=2089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}